Association of Therapy for Autoimmune Disease With Myelodysplastic Syndromes and Acute Myeloid Leukemia
Authors:
Open Access
- 1 July 2017
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Oncology
- Vol. 3 (7) , 936-943
Abstract
Therapy-related secondary myeloid neoplasms constitute a spectrum of diseases, including myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), which are serious consequences resulting from the transformation of a myeloid clone induced by cytotoxic therapy or ionizing radiation exposure.1-3 From 10% to 20% of patients diagnosed with myeloid neoplasms have a history of exposure to cytotoxic therapy and/or radiotherapy for treatment of an unrelated, primary malignant or benign disease, such as an autoimmune disease (AID).3,4 The basis of radiotherapy- or chemotherapy-related hematologic malignant disease is proposed to be a loss of DNA repair mechanisms and resulting genomic instability.2,5 The most common therapeutic agents implicated are alkylating compounds, antimetabolites, and topoisomerase inhibitors.1-3,6 Medical literature has highlighted therapy-related myeloid neoplasms after treatment of several nonmalignant diseases, especially inflammatory bowel disease1,7-9 and rheumatoid arthritis.8,10,11 Further confounding this risk for myeloid neoplasms is the nature of AID itself, which is characterized by an incessant, chronically activated inflammatory cascade that has been associated with an increased risk for myeloid malignant neoplasms alone.12Keywords
This publication has 29 references indexed in Scilit:
- Acute myeloid leukemia developing in patients with autoimmune diseasesHaematologica, 2011
- Chronic Immune Stimulation Might Act As a Trigger for the Development of Acute Myeloid Leukemia or Myelodysplastic SyndromesJournal of Clinical Oncology, 2011
- Therapy‐related myeloid neoplasms: pathobiology and clinical characteristicsBritish Journal of Pharmacology, 2011
- A Review of: “Analysis of Observational Health Care Data Using SAS, by D. E. Faries, A. C. Leon, J. M. Haro, and R. L. Obenchain (Eds.).”Journal of Biopharmaceutical Statistics, 2010
- Anti‐thymocyte globulin plus etanercept as therapy for myelodysplastic syndromes (MDS): a phase II studyBritish Journal of Haematology, 2010
- Prolonged responses in patients with MDS and CMML treated with azacitidine and etanerceptBritish Journal of Haematology, 2010
- Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registryAnnals of the Rheumatic Diseases, 2010
- Azathioprine: Association with Therapy-related Myelodysplastic Syndrome and Acute Myeloid LeukemiaThe Journal of Rheumatology, 2010
- Risks of myeloid malignancies in patients with autoimmune conditionsBritish Journal of Cancer, 2009
- Acute Myeloid Leukemia after Azathioprine Treatment for Autoimmune DiseasesCancer Genetics and Cytogenetics, 1998